MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium Twelve of 42 patients (28.6%) in metastatic castration-resistant prostate cancer (mCRPC) cohort achieved ≥ 50% prostate-specific antigen (PSA) reduction (PSA50), including 9 (21.4%) who achieved ≥ 90%...

MacroGenics Announces MGD019 Publication in Cell Reports Medicine ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...

MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020 MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose established for MSS CRC, NSCLC expansion...